Thiogenesis Therapeutics, Corp. (TSXV:TTI)

Canada flag Canada · Delayed Price · Currency is CAD
0.6700
-0.0100 (-1.47%)
Oct 22, 2025, 10:49 AM EDT
-1.47%
Market Cap34.73M
Revenue (ttm)n/a
Net Income (ttm)-5.09M
Shares Out51.84M
EPS (ttm)-0.11
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,100
Average Volume14,252
Open0.6700
Previous Close0.6800
Day's Range0.6700 - 0.6700
52-Week Range0.5100 - 0.8800
Beta0.65
RSI35.92
Earnings DateNov 17, 2025

About Thiogenesis Therapeutics

Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome. The company is headquartered in Toronto, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Patrice Rioux
Country Canada
Stock Exchange TSX Venture Exchange
Ticker Symbol TTI
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.